Ultrasound Breast Screens Useful in Selected Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

CHICAGO--Citing findings from radiological studies performed on more than 10,000 women, Paula Gordon, MD, suggests periodic ultrasound examination of the breast in addition to mammography for women at high risk of breast cancer and who have mammographically dense breasts.

CHICAGO--Citing findings from radiological studies performed onmore than 10,000 women, Paula Gordon, MD, suggests periodic ultrasoundexamination of the breast in addition to mammography for womenat high risk of breast cancer and who have mammographically densebreasts.

She also believes that ultrasonographers should scan the entirebreast in women whose mammograms exhibit a lump or some othersuspicious finding rather than follow the common practice of scanningonly the lump and the surrounding tissue.

Ultrasonography of the full breast takes only a few minutes longerthan a spot scan, and it does not appreciably add to the costof the exam. However, it can uncover unsuspected cancer, saidDr. Gordon, clinical associate professor of radiology, Universityof British Columbia, Vancouver, Canada.

Ultrasound should not take the place of mammography as a breastcancer screening tool, Dr. Gordon said at the annual meeting ofthe Radiological Society of North America. "Ultrasound doesnot show microcalcifications, for example, which are early signsof cancer that show up very well on mammography," she explained.

However, ultrasound could be an adjunct to mammography for certaingroups of women, she advised. One group consists of women whohave no symptoms of breast cancer but who have a strong familyhistory of the disease or a prior personal history of breast cancerand who have radiographically dense breasts.

Another group includes women with breast cancer who are beingconsidered for conservative surgery. "Ultrasound can helpdetermine if other areas of undiagnosed cancer may exist in thebreast, thereby helping to determine how extensive surgical removalshould be," she said.

Dr. Gordon reached these conclusions after completing a studyof breast ultrasound examinations performed on 10,362 women. Ultrasoundidentified a total of 3,533 solid tumors, 37% of which had notbeen seen previously on mammography studies or palpated duringphysical examination.

Of the 328 breast malignancies that were confirmed in the study,37 (more than 11%) were diagnosed by ultrasound alone. These malignanciesranged in size from 4 mm to 2.5 cm, and they represented 2.8%of the tumors that had not been found on mammographic or physicalexamination.

"Mammography remains the gold standard for breast cancerscreening, and, for the vast majority of women, no further examis recommended if a mammogram is negative. However, for a smallgroup of women at high risk for breast cancer, adding ultrasoundto mammography as a screen may improve diagnosis and greatly increasetheir peace of mind," Dr. Gordon said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content